Abstract

The Clinical Core provides patients to support the translational and clinical portions of all Projects of theProstate SPORE. Clinical trial management including protocol administration, patient recruitment and dataentry will be managed by the Core. Patients will be recruited for participation in the SPORE translationalresearch and clinical trials in this core which will operate jointly in the Departments of Urology, RadiationOncology, and Medical Oncology. Database managers in each department will assist in recruiting patientsfor these studies, schedule tests and follow-up appointments, and gather data. Prospective follow-up datacollection in support of the biomarker Project 1 will include serum prostate specific antigen (PSA), physicalexamination, and disease status. Data storage and analysis will be conducted by the Biostatistics Core inclose coordination with the Clinical Core.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
5P50CA091956-08
Application #
7729572
Study Section
Special Emphasis Panel (ZCA1-GRB-I (M1))
Project Start
2008-09-11
Project End
2011-08-31
Budget Start
2008-09-11
Budget End
2009-08-31
Support Year
8
Fiscal Year
2008
Total Cost
$135,894
Indirect Cost

  Institution

Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905

  Publications

Guerrico, Anatilde Gonzalez; Hillman, David; Karnes, Jeffery et al. (2017) Roles of kallikrein-2 biomarkers (free-hK2 and pro-hK2) for predicting prostate cancer progression-free survival. J Circ Biomark 6:1849454417720151
Hearn, Jason W D; AbuAli, Ghada; Reichard, Chad A et al. (2016) HSD3B1 and resistance to androgen-deprivation therapy in prostate cancer: a retrospective, multicohort study. Lancet Oncol 17:1435-1444
Spratt, Daniel E; Evans, Michael J; Davis, Brian J et al. (2015) Androgen Receptor Upregulation Mediates Radioresistance after Ionizing Radiation. Cancer Res 75:4688-96
Lu, Ji; Lonergan, Peter E; Nacusi, Lucas P et al. (2015) The cistrome and gene signature of androgen receptor splice variants in castration resistant prostate cancer cells. J Urol 193:690-8
Urban, Matthew W; Wang, Chenyi; Alizad, Azra et al. (2015) Complex background suppression for vibro-acoustography images. Ultrasonics 56:456-72
Cooperberg, Matthew R; Davicioni, Elai; Crisan, Anamaria et al. (2015) Combined value of validated clinical and genomic risk stratification tools for predicting prostate cancer mortality in a high-risk prostatectomy cohort. Eur Urol 67:326-33
Alshalalfa, Mohammed; Crisan, Anamaria; Vergara, Ismael A et al. (2015) Clinical and genomic analysis of metastatic prostate cancer progression with a background of postoperative biochemical recurrence. BJU Int 116:556-67
Loeb, Stacy; Sanda, Martin G; Broyles, Dennis L et al. (2015) The prostate health index selectively identifies clinically significant prostate cancer. J Urol 193:1163-9
Zhong, Jian; Ding, Liya; Bohrer, Laura R et al. (2014) p300 acetyltransferase regulates androgen receptor degradation and PTEN-deficient prostate tumorigenesis. Cancer Res 74:1870-1880
Klee, Eric W; Bondar, Olga P; Goodmanson, Marcia K et al. (2014) Mass spectrometry measurements of prostate-specific antigen (PSA) peptides derived from immune-extracted PSA provide a potential strategy for harmonizing immunoassay differences. Am J Clin Pathol 141:527-33

Showing the most recent 10 out of 206 publications